Tiziana Life Sciences (TLSA) Competitors $0.94 -0.04 (-4.09%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TLSA vs. TSHA, CCCC, PROK, GHRS, MGTX, ORGO, VYGR, RNAC, TKNO, and AMLXShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Taysha Gene Therapies (TSHA), C4 Therapeutics (CCCC), ProKidney (PROK), GH Research (GHRS), MeiraGTx (MGTX), Organogenesis (ORGO), Voyager Therapeutics (VYGR), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Taysha Gene Therapies C4 Therapeutics ProKidney GH Research MeiraGTx Organogenesis Voyager Therapeutics Cartesian Therapeutics Alpha Teknova Amylyx Pharmaceuticals Taysha Gene Therapies (NASDAQ:TSHA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Which has higher earnings and valuation, TSHA or TLSA? Tiziana Life Sciences has lower revenue, but higher earnings than Taysha Gene Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$15.45M20.30-$111.57M-$0.20-7.65Tiziana Life SciencesN/AN/A-$17.69MN/AN/A Does the media favor TSHA or TLSA? In the previous week, Tiziana Life Sciences had 6 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 2 mentions for Taysha Gene Therapies. Tiziana Life Sciences' average media sentiment score of 0.59 beat Taysha Gene Therapies' score of 0.18 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TSHA or TLSA more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -888.18%. Tiziana Life Sciences' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-888.18% -168.91% -44.12% Tiziana Life Sciences N/A N/A N/A Do analysts recommend TSHA or TLSA? Taysha Gene Therapies presently has a consensus price target of $6.38, suggesting a potential upside of 316.67%. Given Taysha Gene Therapies' higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community believe in TSHA or TLSA? Taysha Gene Therapies received 3 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. Likewise, 76.15% of users gave Taysha Gene Therapies an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes9976.15% Underperform Votes3123.85% Tiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Do institutionals & insiders believe in TSHA or TLSA? 77.7% of Taysha Gene Therapies shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, TSHA or TLSA? Taysha Gene Therapies has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. SummaryTiziana Life Sciences beats Taysha Gene Therapies on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.51M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book18.755.324.665.02Net Income-$17.69M$153.56M$119.06M$225.46M7 Day Performance-5.35%0.13%0.80%0.37%1 Month Performance0.29%15.23%5.65%3.57%1 Year Performance43.21%41.14%36.75%29.43% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences1.451 of 5 stars$0.94-4.1%N/A+44.6%$100.51MN/A0.008News CoverageGap DownTSHATaysha Gene Therapies1.6547 of 5 stars$1.99+1.0%$6.38+220.4%-35.8%$407.83M$15.45M-9.95180News CoverageCCCCC4 Therapeutics2.2288 of 5 stars$5.89-1.0%$10.50+78.3%+325.0%$405.27M$29.38M-3.10150Upcoming EarningsNews CoveragePositive NewsPROKProKidney1.5082 of 5 stars$1.75+1.4%$4.50+157.1%-6.9%$401.35MN/A-2.973Gap UpGHRSGH Research1.7907 of 5 stars$7.65+1.3%$36.67+379.3%+15.4%$398.01MN/A-11.4210Short Interest ↑News CoverageMGTXMeiraGTx4.4545 of 5 stars$5.86+1.0%$22.50+284.0%+15.3%$380.31M$14.02M-4.19300ORGOOrganogenesis4.0766 of 5 stars$2.80-2.4%$4.88+74.1%+21.4%$371.20M$448.39M-21.54950News CoverageVYGRVoyager Therapeutics4.2127 of 5 stars$6.75+2.7%$17.43+158.2%+6.9%$368.08M$250.01M24.11100Upcoming EarningsAnalyst UpgradeRNACCartesian Therapeutics3.3474 of 5 stars$20.58-6.9%$43.00+108.9%N/A$366.24M$54.10M0.0037Positive NewsTKNOAlpha Teknova1.0115 of 5 stars$6.79+2.1%$5.00-26.4%+267.7%$361.91M$36.68M-7.30240Upcoming EarningsNews CoverageAMLXAmylyx Pharmaceuticals4.0918 of 5 stars$5.31+8.4%$14.57+174.4%-67.0%$361.11M$298.76M-2.17200Positive News Related Companies and Tools Related Companies TSHA Competitors CCCC Competitors PROK Competitors GHRS Competitors MGTX Competitors ORGO Competitors VYGR Competitors RNAC Competitors TKNO Competitors AMLX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLSA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
